The Endocannabinoid Palmitoylethanolamide for Bipolar Depression


Eligible patients will be men and women aged 18-60 years with a diagnosis of Bipolar Disorder according to the Diagnostic and Statistical Manual of Mental Disorders (Structured Clinical Interview), Fifth Edition, (DSM5), with a score of ≥16 on the 17-item HAM-D; currently in use of at least one FDA approved mood stabilizer and no antidepressant; medically and neurologically healthy on the basis of medical history, physical examination, and screening laboratories; no cannabis use in the past 60 days.

Inclusion Criteria:

  • Adults, ages 18-65
  • Diagnostic criteria for single-episode MDD or recurrent MDD, without psychotic features, treatment-resistant to standard antidepressants


Courtney Vecera